Source comparison
CJC-1295 no DAC & Ipamorelin Beginners Guide: Comparison Table
The table below contrasts CJC-1295 no DAC and Ipamorelin across mechanism, half-life, dosing patterns, and selectivity. Understanding these differences clarifies why they're combined rather than used interchangeably. Receptor Target GHRH receptors on pituitary
This comparison does not assign a generated winner or score.
- The table below contrasts CJC-1295 no DAC and Ipamorelin across mechanism, half-life, dosing patterns, and selectivity. Understanding these differences clarifies why they're combined rather than used interchangeably.
- Receptor Target
- GHRH receptors on pituitary somatotrophs
- Ghrelin receptors (GHS-R1a) centrally and peripherally
- Different pathways—complementary, not redundant
- Primary Mechanism
- Amplifies existing GH pulse amplitude
- Triggers additional GH pulses
- GHRH analog makes pulses bigger; ghrelin mimetic makes them more frequent
- Half-Life
- ~30 minutes (vs 7 min for endogenous GHRH)
- ~2 hours
- Both clear quickly, preserving pulsatile physiology
- Typical Research Dose
- 100–200mcg per injection
- 1:1 ratio is standard
- Prolactin Elevation
- Minimal to none
- None
- Ipamorelin is uniquely selective among ghrelin mimetics
- Cortisol Elevation
- Avoids the ACTH stimulation seen with GHRP-2 and GHRP-6
- Hunger Stimulation
- Minimal (significantly less than GHRP-6)
- Ghrelin mimetics can increase appetite; Ipamorelin does so weakly
- Injection Frequency in Research Models
- 1–3 times daily
- Morning + pre-bed dosing most common